Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aptose Biosciences (APTO) stocks in Canada

Learn how to easily invest in Aptose Biosciences stocks.

Aptose Biosciences is a biotechnology business based in the US. Aptose Biosciences stocks (APTO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.23 – a decrease of 11.59% over the previous week. Aptose Biosciences employs 39 staff and has a market cap (total outstanding stock value) of $120.2 million.

How to buy shares in Aptose Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – APTO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aptose Biosciences stock price (NASDAQ:APTO)

Use our graph to track the performance of APTO stocks over time.

Aptose Biosciences shares at a glance

Information last updated 2022-01-17.
Latest market close$1.22
52-week range$1.08 - $7.20
50-day moving average $1.89
200-day moving average $3.12
Wall St. target price$9.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.63

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Aptose Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Aptose Biosciences price performance over time

Historical closes compared with the close of $1.22 from 2022-01-19

1 week (2022-01-11) -12.23%
1 month (2021-12-16) -17.01%
3 months (2021-10-16) N/A
6 months (2021-07-20) -57.19%
1 year (2021-01-20) -71.82%
2 years (2020-01-17) -79.25%
3 years (2019-01-18) 2.21
5 years (2017-01-20) 1.31

Aptose Biosciences financials

Gross profit TTM $0
Return on assets TTM -30.04%
Return on equity TTM -51.18%
Profit margin 0%
Book value $1.00
Market capitalisation $120.2 million

TTM: trailing 12 months

Aptose Biosciences share dividends

We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.

Have Aptose Biosciences's shares ever split?

Aptose Biosciences's shares were split on a 1:12 basis on 5 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.

Aptose Biosciences share price volatility

Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $1.08 up to $7.2. A popular way to gauge a stock's volatility is its "beta".

APTO.US volatility(beta: 1.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 1.117. This would suggest that Aptose Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Aptose Biosciences overview

Aptose Biosciences Inc. , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site